StockNews.AI
HRMY
StockNews.AI
175 days

Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs

1. HRMY posts record Q4 revenue at $201.3M; FY 2024 revenue reaches $714.7M. 2. Guidance for 2025 WAKIX revenue projected at $820-$860M, targeting $1B+ opportunity.

Earnings
-2.44%Current Return
VS
-0.6%S&P 500
$34.1802/25 07:49 AM EDTEvent Start
$33.34502/26 02:22 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

Robust quarter and full-year revenues, coupled with a strong cash balance and transformative guidance, mirror historical biotech surges that boosted stock prices.

How important is it?

The record revenues and transformative outlook enhance investor sentiment and potential market re-rating for HRMY.

Why Long Term?

The ambitious 2025 revenue targets suggest sustained growth, similar to past instances where solid guidance fostered long-term investor confidence.

Related Companies

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced a record $201.3 million in net product revenues for the fourth quarter 2024, and full year 2024 net revenues of $714.7 million, ending the year with $576 million in cash, cash equivalents and investments on the balance sheet. The company has guided 2025 WAKIX® net revenues to $820 - $860 million, targeting a $1B+ opportunity with WAKIX in narcolepsy alone. “2025 is set up to be a transforma.

Related News